Sheff,
This piece is a great find in your DD on Talon. I am an optimist on Talon's chances of approval and really think this company has huge potential written all over it. My understanding from past CC calls is that they would like to market and sell Marqibo for the smaller ALL indication themselves rather than partner with big pharma.
On the other hand, their other drug in development, Menadione, will have their Phase 2 clinical trial results by the end of the year, which is being conducted by the Mayo Clinic. If the results are very positive, I think Menadione will be partnered with big Pharma as it is a therapeutic cream for the treatment/prevention of skin rash in cancer patients using treatment of all approved EGFR inhibitors such as Erbitux, Tarceva,Tykerb,and Vectibix.
